EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences - PubMed (original) (raw)

Review

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences

Olivier Dassonville et al. Crit Rev Oncol Hematol. 2007 Apr.

Abstract

Current development of targeted therapy in oncology is particularly active and concerns principally two types of agents which are monoclonal antibodies (Mabs) and tyrosine kinase inhibitors (TKIs). Epidermal growth factor receptor (EGFR) signaling pathways play a key role in the regulation of cell proliferation, survival and differentiation. Consequently, EGFR is one of the most-studied ligand-receptor systems and specific EGFR inhibition approaches are currently among the most promising and the most advanced in the clinical setting. Cetuximab (Erbitux), belonging to the Mabs family, gefitinib (Iressa) and erlotinib (Tarceva), belonging to the TKIs family, are among the most advanced anti-EGFR drugs at the clinical level. The aim of this review article is to compare at both experimental and clinical levels the key points which govern the activity of these two types of targeting agents.

PubMed Disclaimer

Cited by

Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells.
Noh H, Yan J, Hong S, Kong LY, Gabrusiewicz K, Xia X, Heimberger AB, Li S. Noh H, et al. Oncotarget. 2016 Nov 1;7(44):72021-72032. doi: 10.18632/oncotarget.12458. Oncotarget. 2016. PMID: 27713131 Free PMC article.
Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines.
Solmi R, Lauriola M, Francesconi M, Martini D, Voltattorni M, Ceccarelli C, Ugolini G, Rosati G, Zanotti S, Montroni I, Mattei G, Taffurelli M, Santini D, Pezzetti F, Ruggeri A, Castellani G, Guidotti L, Coppola D, Strippoli P. Solmi R, et al. BMC Cancer. 2008 Aug 8;8:227. doi: 10.1186/1471-2407-8-227. BMC Cancer. 2008. PMID: 18691415 Free PMC article.
Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
Zhang J, Zheng J, Yang Y, Lu J, Gao J, Lu T, Sun J, Jiang H, Zhu Y, Zheng Y, Liang Z, Liu T. Zhang J, et al. Sci Rep. 2015 Dec 22;5:18678. doi: 10.1038/srep18678. Sci Rep. 2015. PMID: 26691448 Free PMC article.
Exploiting Radiation Induction of Antigens in Cancer: Targeted Drug Delivery.
Kapoor V, Singh AK, Lewis CD, Deore S, Hallahan DE. Kapoor V, et al. Int J Mol Sci. 2022 Mar 11;23(6):3041. doi: 10.3390/ijms23063041. Int J Mol Sci. 2022. PMID: 35328459 Free PMC article. Review.
EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992.
Spicer JF, Rudman SM. Spicer JF, et al. Target Oncol. 2010 Dec;5(4):245-55. doi: 10.1007/s11523-010-0140-y. Epub 2010 Jun 24. Target Oncol. 2010. PMID: 20574858 Review.

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences - PubMed (original) (raw)